Bayer

Elly is the world's first empathetic audio companion for patients living with a chronic disease.

BioLum Sciences specializes in bioanalytical chemistry & medical device development centered around our core analysis platform and chemiluminescent chemistry. BioLum uses advanced chemical systems to measure biomarkers in exhaled breath condensate and blood samples. This technology empowers pharmaceutical researchers and clinicians with tools to develop and personalize treatments for patients with chronic diseases such as asthma, chronic obstructive pulmonary disease (COPD), hypertension, and heart failure. We have several medical device products in the pipeline and offer our research & development expertise in assay development and clinical biomarker measurement, with an emphasis on oxidative stress and nitric oxide signaling. With the advent of biomarker analysis for monitoring disease severity and progression (airway inflammation, lung function) there is a desire to shift towards remote patient monitoring via non-invasive biomarkers to improve treatment plans and lower overall costs on the healthcare system. Our initial programs are focused on asthma, COPD, and hypertension. Our breath analysis product, The BioSense AMD (Airway Monitoring Device), provides a ‘window into the lung’ by measuring oxidative stress biomarkers in exhaled breath condensate (EBC). Our test requires no complicated breathing maneuvers, allowing reliable at-home monitoring. These frequent, objective measurements of lung function offer significant patient benefits, provide physicians a tool to optimize treatment, and enable researchers to stratify patients in clinical trials to better understand chronic respiratory disease states. Our blood analysis product measures nitric oxide and nitrative stress metabolites in the blood using a simple finger-prick test. This point-of-care device will provide physicians, researchers, and patients with a critical gauge of endothelial function and cardiovascular health.

At Upside Health, we’re transforming the way chronic pain is assessed and treated. Our software empowers every clinician to deliver cutting-edge chronic pain care. The remote patient monitoring and engagement tools we offer create significant revenue-generating and improved care opportunities without increasing burden on physicians and office staff.

Metagenomi uses metagenomics and machine learning to discover novel genome editing systems for therapeutics development. The company's metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. Metagenomi forges these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific, and have a decreased risk of the immune response. Metagenomi's goal is to revolutionize gene editing for the benefit of patients around the world. The company was founded in 2018 and is headquartered in Emeryville, California.

BioSTL builds regional capacity and fosters collaborative efforts to advance innovation, entrepreneurship, and new company creation that capitalize on St. Louis’ world-class medical and plant biosciences. Through its work, BioSTL promotes economic growth and regional prosperity.

Aparito’s mission is to digitise clinical trials and accelerate drug development by supporting patient-centric clinical trials with the Atom5™ eCOA platform. The Atom5™ platform is Part 11, GDPR and HIPPA compliant and supports clinical trials at scale with video eCOAs, ePROs, Wearables, Telemedicine and eConsent in 193 countries and 125 languages to capture more frequent patient-generated data in the clinic and at home. This moves from relying on sterile, snapshot assessments during clinic visits to continuous, real-time, real-world data utilising novel eCOA and digital biomarkers.

The World's First Smart Toilet Device that Tracks your Health

The Muny is a community outdoor musical performance and recreation center. In this studio, singers may perform without accompaniment or may be accompanied by any instrumental combination, from piano to full orchestra. They inspire people to praise. Likewise, using the choir for congregational songs is a powerful prompt to help worshipers clearly hear the melody and join their voices as one.

CoverCress is a biotechnology company that focuses on research and development of renewable fuel and livestock feed. It specializes in producing an oilseed crop for food, bioenergy, and cattle feed. It specializes in the fields of agriculture, biotechnology, plants, genetics, cover crop, and precision agriculture. CoverCress was founded in 2013 by Jerry Steiner and Dr. Tim Ulmasov and is headquartered in St. Louis Missouri.

Our company, Sky Labs, is developing a ring-type Cardio Tracker, CART to help continuous monitoring of atrial fibrillation which is difficult to diagnose even in a hospital in daily life. According to a disease statistics study released in 2004, atrial fibrillation is a very common chronic disease that occurs in 1 out of 4 people in their 40s or older. As stated in the Atrial Fibrillation Report from the UK's Atrial Fibrillation Association in 2012, the biggest problem is that atrial fibrillation is not diagnosed in 1 in 2 patients because it is not accompanied by severe subjective symptoms and hard to find due to the intermittent properties. To diagnose atrial fibrillation, the following three features of continuous monitoring are essential. Our product, CART, is equipped with these features to fully maximize the benefits of continuous monitoring. 1) Comfortability as a wearable device : You can always wear CART on a daily basis. Additionally, it is even water-proof and dust-proof. So, you don't have to take it off while taking a shower, or washing hands. 2) No-user intervention : By just wearing it on any finger which fits for you, every measurement is performed on the background basis without any intervention. 3) Medical proof & Accuracy : Diagnosis is based on the conventional diagnosis method of cardiologists. By simply wearing CART on user's finger, CART continuously detects atrial fibrillation without any user intervention. CART detects and records atrial fibrillation, so users can track and manage their heart health status. In addition, users can diagnose atrial fibrillation whenever they want and see the results on their smartphone. By merely tapping CART, users can make event logs and analyze atrial fibrillation data at that moment when it occurs. Finally, the collected atrial fibrillation data can be used to help the physician diagnose of the atrial fibrillation. Initial target market is 0.2 million atrial fibrillation patients in Finland. Total target market is 300 million people to diagnose atrial fibrillation and tens of million subjects in clinical trials. Sky Labs is currently conducting clinical trials with the Seoul National University Hospital to verify the device's performance and is analyzing clinical data on heart disease. And, Sky Labs is working with global pharmaceutical company Bayer to make innovative healthcare business.

Boragen develops synthetic chemistry platforms designed to produce next-generation fungicides. The platform supports sustainable farming methods by creating a compound that decreases the probability of fungicide resistance and reduces the amount of chemical applied while maintaining performance and efficacy. The company utilizes boron’s unique properties to design and develop novel solutions targeting needs in crop protection, animal health, and human health. Founded in 2015, Boragen is based in Durham, North Carolina.

proPlant Gesellschaft für Agrar- und Umweltinformatik

DIREVO provides customized solutions for various industries via the development and optimization of biocatalysts with its proprietary ultra-high-throughput screening platform. Serving the Feed & Food industries and chemical / biorefinery businesses, DIREVO products are developed either independently or in conjunction with global leaders such as Genencor (a division of Danisco A/S), AB Enzymes, Roal Ltd. and Nestlé. DIREVO Industrial Biotechnology GmbH is privately owned and located in Cologne, Germany. The shareholders include Wölbern EquityPartner GmbH (Hamburg), NRW Bank (Düsseldorf), TVM Capital (Munich), Danisco A/S (Copenhagen), a private equity firm affiliated with Sparkasse KölnBonn (Cologne), SandersMorrisHarris EnzymesLLC (New York), Mulligan BioCapital (Hamburg), and several private investors.

yet2.com provides intellectual property consulting and licensing services to world-class clients around the globe. Yet2.com Inc. and its online marketplace were founded in 1999 to promote Open Innovation, with original investments from Siemens, Bayer, Honeywell, DuPont, Procter & Gamble, Caterpillar, and NTT Leasing. The privately held company has offices in the United States, Europe, and Japan. The web site now has over 120,000 registered marketplace users including many of the Fortune 500 and over 16,000 smaller technology companies. In addition to its core team, yet2.com has created a wide network of Open Innovation partners covering many of the technology-rich countries around the world as well as relationships with open innovation organizations, technical expert networks, SME networks, technical magazines, online technical communities, and technology brokers. These provide market-wide access to technologies and needs in countries such as Russia, China, India, Korea, Brazil, South Africa, Japan, the US, and the EU.